Kailera Therapeutics Inc (KLRA)

$21.67 +0.84 (4.03%)
Market Cap 2.70B
Revenue (ttm) 0.00
Net Income (ttm) -148.96M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 581,700
Avg Vol N/A
Day's Range N/A - N/A
Shares Out 129.57M
Stochastic %K 71%
Beta N/A
Analysts Strong Sell
Price Target $42.75

Company Profile

Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-ag...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 317 0290
Address:
180 Third Avenue, 4th Floor, Waltham, United States
nlrmandate
nlrmandate Jun. 24 at 9:32 PM
@IM11 not raining on anyone's parade. All three of $VKTX $GPCR and $KLRA will be bought by mid 2027 IMO. There are several BP who wish to play in the obesity sandbox and these three are the only clinical biotechs in the weight loss sector with seriously good/great pipelines. And, they're all different enough from each other to attract buyers. Long and insanely
0 · Reply
biolover
biolover Jun. 24 at 6:30 PM
The volume story is still there and likely hiding news beyond $VKTX amylin is not the whole story? anemic volume for $KLRA and $GPCR. ? Why it is not a fair game and others will know early ?
2 · Reply
Bagholding_VKTX
Bagholding_VKTX Jun. 24 at 2:43 AM
$VKTX I agree, today's movement was clearly from Viking specific flows. What I noticed, and some of you may also have noticed, is $KLRA and $GPCR 's movement compared to Viking. Both surged, as expected, in tandem with VKTX, in the last few days. However, today, KLRA fell sharply and GPCR is flat. In addition, please zoom out on Viking's chart. The recent surge is one of the steepest inclines (excluding data releases), suggesting that there were heavy, heavy buying flows in the past few days. Moreover, amylin's announcement still has not come. This is not a coincidence. The inflows into Viking and outflows from KLRA and GPCR could mean institutions may think a partnership/BO could be coming soon, with Viking. It does not mean there WILL be a partnership/buyout. But, everything always somehow leaks. It is extremely likely that this leak may have been that there are currently discussions going on and that they are getting more serious. I remain extremely bullish. $350 is likely
0 · Reply
History101
History101 Jun. 19 at 8:49 PM
$KLRA 133 watching 6/19/2026
0 · Reply
JohnnyVacs
JohnnyVacs Jun. 18 at 7:59 PM
$VKTX there you go. XBI spiking end of day and this going the opposite. $KLRA spiking. KLRA announcement coming monday. Another one BO before VKTX. Was outperforming the XBI all day and dumps on no volume. It must really be fun to be a short on VKTX. Another day the index outperforms VKTX. Usually Bio’s spike into close for covering reasons. Not VKTX. People don’t want to hold it over the weekend because it can dump 50% like its nothing.
0 · Reply
biolover
biolover Jun. 18 at 7:35 PM
$VKTX rumors $ABBV jets clustered somewhere remote 😂. I personally don’t beleive Abbv will wait long. Could be Vk could be $KLRA These calls could go up 100.000% last 2 year sentiment suggests otherwise but u never know ..
0 · Reply
biolover
biolover Jun. 16 at 10:57 AM
$VKTX Trump JR at $NVO headquarters..and speculation why ? One discussed possibility is needing help with FTC .. the real question is who really needs who ? Novo or Viking ?— could be $KLRA as well although in this case novo will rely on Chinese pts tolerability data.
1 · Reply
PlutoAnalyses
PlutoAnalyses Jun. 11 at 3:29 PM
STRUCTURE THERAPEUTICS The full analysis of $GPCR is now available online on my Substack! If you're interested in the GLP-1 market or companies like $VKTX or $KLRA, this post is worth a read. I've found that safety might matter more than efficacy when it comes to GLP-1s, which is where GPCR really stands out. You can check out the article for free here: https://open.substack.com/pub/plutoanalyses/p/structure-therapeutics-analysis-whats?utm_source=app-post-stats-page&r=5e6tza&utm_medium=ios $XBI $IBB
0 · Reply
GreenHawkz
GreenHawkz Jun. 10 at 6:08 PM
$VKTX promise promise promise you . $KLRA & $GPCR will make you more money than this ever will. The CEO hasn’t zero interest in bringing a drug to market. He is using you for compensation and will dilute you in due time.
1 · Reply
NVDAMillionaire
NVDAMillionaire Jun. 10 at 9:16 AM
$KLRA Really good write-up that perfectly summarizes KLRA's present situation. So if you want to bring your KLRA knowledge up to date or just discover KLRA, this is required reading. https://everyticker.com/quote/KLRA/analysis/kailera-therapeutics-a-1-3-billion-bet-on-obesity-market-leadership-with-clinical-proof-still-pending-nasdaq-klra
0 · Reply
Latest News on KLRA
Kailera appoints Kathleen Tregoning as chief corporate affairs officer

2026-06-29T11:45:19.000Z - 1 day ago

Kailera appoints Kathleen Tregoning as chief corporate affairs officer

Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer

Jun 29, 2026, 7:30 AM EDT - 1 day ago

Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer

Biotech ETF Index Surges 10% After Rebalance

Jun 25, 2026, 11:31 AM EDT - 5 days ago

Biotech ETF Index Surges 10% After Rebalance

ALKS APGE DFTX DYN KYMR MANE MIRM

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Jun 5, 2026, 7:32 PM EDT - 24 days ago

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Kailera Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 10:30 AM EDT - 26 days ago

Kailera Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

May 28, 2026, 4:05 PM EDT - 4 weeks ago

Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates

May 26, 2026, 4:02 PM EDT - 4 weeks ago

Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates

Kailera Therapeutics Earnings release: Q1 2026

May 26, 2026, 4:00 PM EDT - 4 weeks ago

Kailera Therapeutics Earnings release: Q1 2026

Kailera Therapeutics Quarterly report: Q1 2026

May 26, 2026, 4:00 PM EDT - 4 weeks ago

Kailera Therapeutics Quarterly report: Q1 2026

Kailera Therapeutics Slides: Company presentation

May 26, 2026, 7:00 AM EDT - 5 weeks ago

Kailera Therapeutics Slides: Company presentation

Hengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions

May 13, 2026, 7:30 AM EDT - 6 weeks ago

Hengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions

Kailera Therapeutics initiated with an Outperform at Evercore ISI

2026-05-12T15:50:12.000Z - 7 weeks ago

Kailera Therapeutics initiated with an Outperform at Evercore ISI

Kailera Therapeutics initiated with an Outperform at Leerink

2026-05-12T11:41:46.000Z - 7 weeks ago

Kailera Therapeutics initiated with an Outperform at Leerink

LLY NVO

Kailera Therapeutics initiated with a Buy at TD Cowen

2026-05-12T09:37:06.000Z - 7 weeks ago

Kailera Therapeutics initiated with a Buy at TD Cowen

Kailera Therapeutics initiated with an Outperform at William Blair

2026-05-12T09:15:10.000Z - 7 weeks ago

Kailera Therapeutics initiated with an Outperform at William Blair

Kailera Therapeutics initiated with an Overweight at JPMorgan

2026-05-12T09:10:43.000Z - 7 weeks ago

Kailera Therapeutics initiated with an Overweight at JPMorgan

Kailera Therapeutics initiated with a Buy at Jefferies

2026-05-12T09:06:18.000Z - 7 weeks ago

Kailera Therapeutics initiated with a Buy at Jefferies

Kailera Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Apr 20, 2026, 4:05 PM EDT - 2 months ago

Kailera Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Kailera Stock (KLRA) Rockets 68% after IPO in Race for $150B Obesity Market

2026-04-17T18:40:18.000Z - 2 months ago

Kailera Stock (KLRA) Rockets 68% after IPO in Race for $150B Obesity Market

AMGN GPCR LLY PFE

Kailera surges over 60% in Nasdaq debut as weight-loss drug race heats up

Apr 17, 2026, 1:41 PM EDT - 2 months ago

Kailera surges over 60% in Nasdaq debut as weight-loss drug race heats up

Kailera Therapeutics opens at $26, IPO priced at $16 per share

2026-04-17T17:30:55.000Z - 2 months ago

Kailera Therapeutics opens at $26, IPO priced at $16 per share

Kailera Therapeutics indicated to open at $21, IPO priced at $16

2026-04-17T15:45:23.000Z - 2 months ago

Kailera Therapeutics indicated to open at $21, IPO priced at $16

Kailera Therapeutics indicated to open at $24, IPO priced at $16

2026-04-17T14:40:16.000Z - 2 months ago

Kailera Therapeutics indicated to open at $24, IPO priced at $16

Kailera Therapeutics 39.06M share IPO priced at $16.00

2026-04-17T00:05:37.000Z - 2 months ago

Kailera Therapeutics 39.06M share IPO priced at $16.00

Kailera Therapeutics Announces Pricing of Initial Public Offering

Apr 16, 2026, 7:25 PM EDT - 2 months ago

Kailera Therapeutics Announces Pricing of Initial Public Offering

Kailera Therapeutics Registration statement: Registration filing

Apr 13, 2026, 8:00 AM EDT - 2 months ago

Kailera Therapeutics Registration statement: Registration filing

Kailera Therapeutics files for US IPO

Mar 27, 2026, 4:15 PM EDT - 3 months ago

Kailera Therapeutics files for US IPO

Kailera Therapeutics IPO Registration Document (S-1)

Mar 27, 2026, 4:02 PM EDT - 3 months ago

Kailera Therapeutics IPO Registration Document (S-1)

nlrmandate
nlrmandate Jun. 24 at 9:32 PM
@IM11 not raining on anyone's parade. All three of $VKTX $GPCR and $KLRA will be bought by mid 2027 IMO. There are several BP who wish to play in the obesity sandbox and these three are the only clinical biotechs in the weight loss sector with seriously good/great pipelines. And, they're all different enough from each other to attract buyers. Long and insanely
0 · Reply
biolover
biolover Jun. 24 at 6:30 PM
The volume story is still there and likely hiding news beyond $VKTX amylin is not the whole story? anemic volume for $KLRA and $GPCR. ? Why it is not a fair game and others will know early ?
2 · Reply
Bagholding_VKTX
Bagholding_VKTX Jun. 24 at 2:43 AM
$VKTX I agree, today's movement was clearly from Viking specific flows. What I noticed, and some of you may also have noticed, is $KLRA and $GPCR 's movement compared to Viking. Both surged, as expected, in tandem with VKTX, in the last few days. However, today, KLRA fell sharply and GPCR is flat. In addition, please zoom out on Viking's chart. The recent surge is one of the steepest inclines (excluding data releases), suggesting that there were heavy, heavy buying flows in the past few days. Moreover, amylin's announcement still has not come. This is not a coincidence. The inflows into Viking and outflows from KLRA and GPCR could mean institutions may think a partnership/BO could be coming soon, with Viking. It does not mean there WILL be a partnership/buyout. But, everything always somehow leaks. It is extremely likely that this leak may have been that there are currently discussions going on and that they are getting more serious. I remain extremely bullish. $350 is likely
0 · Reply
History101
History101 Jun. 19 at 8:49 PM
$KLRA 133 watching 6/19/2026
0 · Reply
JohnnyVacs
JohnnyVacs Jun. 18 at 7:59 PM
$VKTX there you go. XBI spiking end of day and this going the opposite. $KLRA spiking. KLRA announcement coming monday. Another one BO before VKTX. Was outperforming the XBI all day and dumps on no volume. It must really be fun to be a short on VKTX. Another day the index outperforms VKTX. Usually Bio’s spike into close for covering reasons. Not VKTX. People don’t want to hold it over the weekend because it can dump 50% like its nothing.
0 · Reply
biolover
biolover Jun. 18 at 7:35 PM
$VKTX rumors $ABBV jets clustered somewhere remote 😂. I personally don’t beleive Abbv will wait long. Could be Vk could be $KLRA These calls could go up 100.000% last 2 year sentiment suggests otherwise but u never know ..
0 · Reply
biolover
biolover Jun. 16 at 10:57 AM
$VKTX Trump JR at $NVO headquarters..and speculation why ? One discussed possibility is needing help with FTC .. the real question is who really needs who ? Novo or Viking ?— could be $KLRA as well although in this case novo will rely on Chinese pts tolerability data.
1 · Reply
PlutoAnalyses
PlutoAnalyses Jun. 11 at 3:29 PM
STRUCTURE THERAPEUTICS The full analysis of $GPCR is now available online on my Substack! If you're interested in the GLP-1 market or companies like $VKTX or $KLRA, this post is worth a read. I've found that safety might matter more than efficacy when it comes to GLP-1s, which is where GPCR really stands out. You can check out the article for free here: https://open.substack.com/pub/plutoanalyses/p/structure-therapeutics-analysis-whats?utm_source=app-post-stats-page&r=5e6tza&utm_medium=ios $XBI $IBB
0 · Reply
GreenHawkz
GreenHawkz Jun. 10 at 6:08 PM
$VKTX promise promise promise you . $KLRA & $GPCR will make you more money than this ever will. The CEO hasn’t zero interest in bringing a drug to market. He is using you for compensation and will dilute you in due time.
1 · Reply
NVDAMillionaire
NVDAMillionaire Jun. 10 at 9:16 AM
$KLRA Really good write-up that perfectly summarizes KLRA's present situation. So if you want to bring your KLRA knowledge up to date or just discover KLRA, this is required reading. https://everyticker.com/quote/KLRA/analysis/kailera-therapeutics-a-1-3-billion-bet-on-obesity-market-leadership-with-clinical-proof-still-pending-nasdaq-klra
0 · Reply
JohnnyVacs
JohnnyVacs Jun. 3 at 4:38 PM
$VKTX only 400M to go in Market Cap before $KLRA surpasses Viking.
0 · Reply
Merlintrader
Merlintrader May. 18 at 9:28 PM
$KLRA The 3 Biggest Insider Buys of May 2026: $KLRA, $ODTX and $ARTV https://www.merlintrader.com/insider-buys-may2026/
0 · Reply
biolover
biolover May. 18 at 5:43 PM
$VKTX volume is 10x $GPCR and $KLRA Volume didn’t matter in old days. I am not comparing drugs here ( if it matters as this still all about drugs ) as institutions seem to have little insight into data. But still intriguing to see that ?
1 · Reply
biolover
biolover May. 11 at 2:48 PM
$VKTX looking at $KLRA and $GPCR volumes last few days. All day trading and price manipulation. Not serious new investors. A lot of VK is market makers as well
0 · Reply
JohnnyVacs
JohnnyVacs May. 1 at 4:10 PM
$VKTX $KLRA Is the much better and safer buy here! Management actually cares! BL is actually bearish on his own company. All he wants is more option compensation!
0 · Reply
JohnnyVacs
JohnnyVacs Apr. 29 at 7:59 PM
$VKTX $KLRA About to pass VIKING THERAPEUTICS Market Cap. Crazy times.
1 · Reply
PlutoAnalyses
PlutoAnalyses Apr. 29 at 5:56 PM
$ABBV CMO affirmed co interest in obesity agents that augment weight loss and maintain tolerability. Its an interesting spot for $VKTX because they are such a gread target on paper, but an acquisition would be really expensive since they have funding money and thus leverage other companies wouldnt have. $KLRA might be a bit early in development compared to VKTX so VKTX makes most sence, but its going to be expensive. Curious about Vikings future, follow me to stay up to date. I will publish more articles on VKTX's future catalysts.
0 · Reply
NYG4ever
NYG4ever Apr. 24 at 7:47 PM
$KLRA mega dump
0 · Reply
Bagholding_VKTX
Bagholding_VKTX Apr. 23 at 12:36 PM
$VKTX Just noticed something on $KLRA 's investor relations website. When you are in the SEC filings section and try to filter, there is a category called "Mergers & Acquisitions". Viking does not have this category. What this means for me is the following: I believe KLRA's management did this IPO with the goal of being more transparent with their financial information and promote an acquisition. Thus, I believe KLRA's management will want to sell, even if the price is lower than what it could be, similar to MTSR. Viking is the opposite, as we all know, management wants the highest that it can possibly get because they believe that VK2735 is the best in everything, which I absolutely agree on. However, based on this, I will also be buying some KLRA shares because I believe they could be acquired at a smaller premium, like MTSR. This does not change the Viking thesis, I still believe an acquisition in the 30-40B range is coming.
3 · Reply
MorganHoratio
MorganHoratio Apr. 18 at 12:31 PM
$KLRA: Clinical‑stage biopharma, speculative “unwritten story,” but liquidity is a risk. $AVEX: Cancer drug developer with upcoming data readouts — early pattern looks like HOOD. $NBIS: AI infrastructure play, strong narrative but fierce competition — watch for margin bottom. $HIMS: Telehealth + consumer brand, stable subs, but valuation is no longer cheap — more mid‑term hold. $ONDS: Radar/communication + defense/drone, highly volatile, event‑driven.
3 · Reply
STOCKINSIGHT69
STOCKINSIGHT69 Apr. 18 at 12:03 PM
I called $HOOD early as a high-upside play — still tracking, but I’m always hunting for the next asymmetric setup. Current watchlist (high risk / high reward focus): $KLRA → Clinical-stage biotech. Pure speculation here — “story still forming.” Low liquidity = position sizing is key. $AVEX → Oncology pipeline + upcoming data catalysts. Early structure reminds me of pre-move setups — watching closely. $NBIS → AI infra exposure. Strong narrative tailwind, but margins + competition will decide if this re-rates. HIMS → Telehealth + consumer brand. Solid subscription model, but not cheap anymore. More swing/position trade vs breakout. ONDS → Defense + drone tech. Volatile, headline-driven — can move FAST both ways. This is not about certainty — it’s about risk/reward and timing. I’m lining up my next potential 10x candidate — will share soon. Stay selective. The market rewards positioning, not chasing.
2 · Reply